Premium
Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen‐B Genotype and Allopurinol Dosing
Author(s) -
Hershfield M S,
Callaghan J T,
Tassaneeyakul W,
Mushiroda T,
Thorn C F,
Klein T E,
Lee M T M
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.209
Subject(s) - dosing , allopurinol , pharmacogenetics , genotype , medicine , pharmacology , biology , genetics , gene
Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)‐B, HLA‐B*58:01 , associates strongly with allopurinol‐induced SCAR. We have summarized the evidence from the published literature and developed peer‐reviewed guidelines for allopurinol use based on HLA‐B genotype. Clinical Pharmacology & Therapeutics (2013); 93 2, 153–158. doi: 10.1038/clpt.2012.209